Novel mutations of the MET proto-oncogene in papillary renal carcinomas. - Wikidata - awgldk - TriplyDB

Novel mutations of the MET proto-oncogene in papillary renal carcinomas.

Novel mutations of the MET proto-oncogene in papillary renal carcinomas.

http://www.wikidata.org/entity/Q42815807

about

Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase.Metabolism of kidney cancer: from the lab to clinical practice The MET axis as a therapeutic target.An overview of the c-MET signaling pathway MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?Met in urological cancers MET: a critical player in tumorigenesis and therapeutic target c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method.Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma Choosing the right cell line for renal cell cancer research Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection Biology of MET: a double life between normal tissue repair and tumor progression Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability.Met-Independent Hepatocyte Growth Factor-mediated regulation of cell adhesion in human prostate cancer cells.Random mutagenesis-PCR to introduce alterations into defined DNA sequences for validation of SNP and mutation detection methods.Somatic mutation of epidermal growth factor receptor in a small subset of cutaneous squamous cell carcinoma.Circulating tumor DNA profiling by next generation sequencing reveals heterogeneity of crizotinib resistance mechanisms in a gastric cancer patient with MET amplification.Germline met mutations in mice reveal mutation- and background-associated differences in tumor profiles.Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib.Role of chromosome 3p12-p21 tumour suppressor genes in clear cell renal cell carcinoma: analysis of VHL dependent and VHL independent pathways of tumorigenesis.Genomic Analysis as the First Step toward Personalized Treatment in Renal Cell Carcinoma Oncogenic mutants of RON and MET receptor tyrosine kinases cause activation of the beta-catenin pathway.Molecular sub-classification of renal epithelial tumors using meta-analysis of gene expression microarrays.MET receptor sequence variants R970C and T992I lack transforming capacity.Molecular diagnosis and therapy of kidney cancer.The genetic basis of kidney cancer: a metabolic disease The Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in Cancer Development of c-MET pathway inhibitors.Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions.Integrative genome-wide expression profiling identifies three distinct molecular subgroups of renal cell carcinoma with different patient outcome Loss of glutathione peroxidase 3 expression is correlated with epigenetic mechanisms in endometrial adenocarcinoma.Genetic and epigenetic alterations during renal carcinogenesis.Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas.Dysregulation of Met receptor tyrosine kinase activity in invasive tumors Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.Signaling pathways in renal cell carcinoma.The role of the c-Met pathway in lung cancer and the potential for targeted therapy.Impact of genetics on the diagnosis and treatment of renal cancer.

P2860

Q24307789-E5585302-4549-4E44-B1E2-62C923C8D7B0 Q24600512-047E3A59-1E3E-4E27-A06B-B19B0B803A3D Q24609682-189235A5-54CF-44FE-874B-2B7B782E7C3B Q24633986-AF2A6759-0BF3-4817-AFF5-4D2C81156AD4 Q24646295-28DDE074-7F11-4144-8786-0C34D55FD772 Q26748581-B09CC92F-6202-4A29-9B2B-B5CF18466C3A Q26864988-8E1B6B91-22DA-4EFF-8ED9-32636B9FAEBD Q27008925-F484F66F-E95D-4332-B7DD-AEDC06628E7A Q27649203-46A8A71D-D503-40EA-86AC-237CEA449F43 Q27851704-36572A59-D46E-4152-B72B-A9851E61EBD4 Q27851979-693B9CB6-2BB3-4106-8843-C4B5852604F2 Q28073283-EFD6698B-96DF-45F2-B569-D4876B7207C4 Q28074834-6F3A590F-D28F-4823-992D-56E6FB0E2F3A Q28085247-927F7B7F-7BD9-44ED-BF27-0F559872E0FB Q30374663-A586B454-4A5C-49F3-880A-4A7CFB7C63B4 Q30446159-2AB19C68-6C71-463A-AB28-2D0E16DF8F34 Q32163857-61D0F759-D4FD-4228-B1DC-F0141864CE16 Q33671646-C1BEC58B-2BD4-48FC-9463-E51189C66C76 Q33688625-5FF552A0-C8D3-4FAF-97CE-49BA46684260 Q33737789-82C2E827-5A06-49BB-9866-1B60DCB558F1 Q33880542-53945E31-5633-4C16-9C5C-1267EB6EAB65 Q33918504-F9FA52CE-5B2F-41C4-9EDC-A86906AA22BE Q33947929-EA29F789-8C47-43C5-9AD1-6C40C26248E8 Q33969327-F482DED1-75E3-4E89-9AE0-6029E0133649 Q33982903-FBF0B0D4-14D9-442E-83C9-21BFCE0BCB0B Q34033952-97E62C1F-E00C-4D4B-9988-F82910A40294 Q34065685-7788D753-9B61-4914-ADC2-4AAA4CAF8DA8 Q34087148-50761BDD-B9CF-48D0-AB86-5E3D8ACCD0D1 Q34141913-223BE51A-C9A9-4008-B114-9D824FE33CD9 Q34198905-CC5F0CC4-86CE-4FC2-AA83-945E7B4B2DBD Q34206531-1AA095BB-B6DA-46A8-9052-6ED2EF35C955 Q34348285-C565E2EB-FF84-459C-B8AB-D115C7B261B1 Q34461690-64BB7D92-FD69-40F0-A080-1C9977A9608D Q34467232-ABDCB854-739F-475E-87E9-592150D05457 Q34533693-23C4D847-7D04-4D2E-8D8A-56772BC3E330 Q34584046-2FD1F219-DE9F-4447-B379-840EB1B16203 Q34608416-B736B783-EC73-4509-AD21-FD191A165E42 Q34978827-E9D137F5-43F5-4B94-B853-834C54322CA4 Q35146937-F4589568-3B1A-4D1C-95FB-B3E0BC14493E Q35189579-22FB1C8B-AA05-4514-A8DC-58FCD59185DE

P2860

Novel mutations of the MET proto-oncogene in papillary renal carcinomas.

http://www.wikidata.org/entity/Q42815807

description

1999 nî lūn-bûn

@nan

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

1999年论文

@zh

1999年论文

@zh-cn

name

Novel mutations of the MET proto-oncogene in papillary renal carcinomas.

@en

Novel mutations of the MET proto-oncogene in papillary renal carcinomas.

@nl

type

label

Novel mutations of the MET proto-oncogene in papillary renal carcinomas.

@en

Novel mutations of the MET proto-oncogene in papillary renal carcinomas.

@nl

prefLabel

Novel mutations of the MET proto-oncogene in papillary renal carcinomas.

@en

Novel mutations of the MET proto-oncogene in papillary renal carcinomas.

@nl

P1433

Q42815807-9036E10F-39AE-40F9-81E6-4D4222A3A403

P1476

Q42815807-75518774-690B-463A-8F5A-71C4B4EFFF48

P2093

Q42815807-0AB64938-7274-4460-B1E6-F4AAD85A3316

Q42815807-17B3FEA9-6537-47FD-91FD-05B656AE7DA5

Q42815807-1A1330ED-DF75-434B-8DFC-AA953B48AD2F

Q42815807-4C71FAC1-2CB7-4C7A-AF89-A10D564E5DD4

Q42815807-540E3FE1-B7A5-472C-B100-C0B5B9F501FC

Q42815807-71705DCD-1413-44B4-95F1-954A41E51538

Q42815807-7AD6D963-BDCD-41DE-A589-4DB3910535A5

Q42815807-7BE81413-CD35-4B46-AB11-7C72B8D95906

Q42815807-98564A0B-F69F-45D3-9B82-850D17D8E101

Q42815807-9FCB05CF-F40E-47E2-9A96-EC7718FBA544

P2888

Q42815807-B22F334B-C257-4816-ADC4-FEB76A6CC50C

P304

Q42815807-818DBD02-B34F-4315-A800-2F0A702ED835

P31

Q42815807-4F38DE7C-23E1-4C90-8F9C-F9A18DEE56D0

P356

Q42815807-282C613F-3B90-424B-B4FB-BE4119AA23F5

P407

Q42815807-22D4BAEA-4D30-4265-AF69-991B0A7E3A26

P433

Q42815807-7269CC05-B6B0-4184-843B-46984E4FCB04

P478

Q42815807-2C39B416-612D-4CDD-B679-7C0C7966E943

P50

Q42815807-22862EB9-90B9-4DA1-8DFE-91B36EF1D81A

Q42815807-724D80EA-DD49-4D6A-B81C-60F1DEB41AF2

Q42815807-995AB86E-0845-45B9-9F3E-7AC325BCC591

Q42815807-A64C240E-724C-4457-ABC4-3496EF65D930

P577

Q42815807-E4061A92-DF4E-477D-ADB2-E02B3B0D9AE1

P5875

Q42815807-4C8FCA40-BB18-453E-B8D7-4F8B38ECE916

P6179

Q42815807-4760368C-9C7F-4CBA-A77A-190A70302178

P698

Q42815807-58E14F9C-D1D5-49D4-A078-E365650E548D

P356

P1433

P1476

Novel mutations of the MET proto-oncogene in papillary renal carcinomas

@en

P2093

Bergerheim U

http://www.w3.org/2001/XMLSchema#string

Brauch H

http://www.w3.org/2001/XMLSchema#string

Decker J

http://www.w3.org/2001/XMLSchema#string

Gerrard B

http://www.w3.org/2001/XMLSchema#string

Jenkins R

http://www.w3.org/2001/XMLSchema#string

Junker K

http://www.w3.org/2001/XMLSchema#string

Kinjerski T

http://www.w3.org/2001/XMLSchema#string

Linehan WM

http://www.w3.org/2001/XMLSchema#string

Lubensky I

http://www.w3.org/2001/XMLSchema#string

Nakaigawa N

http://www.w3.org/2001/XMLSchema#string

P2888

P304

2343-2350

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.ONC.1202547

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

Stéphane Richard

P577

1999-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12971751

http://www.w3.org/2001/XMLSchema#string

P6179

1045316043

http://www.w3.org/2001/XMLSchema#string

P698

10327054

http://www.w3.org/2001/XMLSchema#string